The Importance of Improving DE&I in Clinical Trials

In the first part of this roundtable discussion, a panel of experts introduce themselves and highlight the challenges industry is seeing with underrepresentation of racial and ethnic groups in clinical trials.

In the second part of this roundtable discussion, participants highlight best practices for reaching underrepresented populations and increasing their awareness of clinical trials.

Participants touch on the different aspects of FDA's recent Diversity Action Plan guidance and how industry must be held accountable for implementing change.

Industry experts discuss the use of decentralized technologies and the potential of artificial intelligence in reaching underrepresented patient populations.

In the fifth and final part of this roundtable discussion, participants discuss the practice of designing technology with patients in mind and share their concluding thoughts on improving diversity in clinical trials.